Jump to: navigation, search
Systematic (IUPAC) name
CAS number 4093-35-0
ATC code A03FA04
PubChem 2446
DrugBank DB09018
Chemical data
Formula C14H22BrN3O2 
Mol. mass 344.248 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 50 to 75% (oral)
78% (intramuscular)
Protein binding 40%
Metabolism Hepatic
Half life 4 to 5 hours
Excretion Renal, 10 to 14% unchanged
Therapeutic considerations
Pregnancy cat.


Legal status

Prescription only

Routes Oral, IM, IV

WikiDoc Resources for Bromopride


Most recent articles on Bromopride

Most cited articles on Bromopride

Review articles on Bromopride

Articles on Bromopride in N Eng J Med, Lancet, BMJ


Powerpoint slides on Bromopride

Images of Bromopride

Photos of Bromopride

Podcasts & MP3s on Bromopride

Videos on Bromopride

Evidence Based Medicine

Cochrane Collaboration on Bromopride

Bandolier on Bromopride

TRIP on Bromopride

Clinical Trials

Ongoing Trials on Bromopride at Clinical

Trial results on Bromopride

Clinical Trials on Bromopride at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Bromopride

NICE Guidance on Bromopride


FDA on Bromopride

CDC on Bromopride


Books on Bromopride


Bromopride in the news

Be alerted to news on Bromopride

News trends on Bromopride


Blogs on Bromopride


Definitions of Bromopride

Patient Resources / Community

Patient resources on Bromopride

Discussion groups on Bromopride

Patient Handouts on Bromopride

Directions to Hospitals Treating Bromopride

Risk calculators and risk factors for Bromopride

Healthcare Provider Resources

Symptoms of Bromopride

Causes & Risk Factors for Bromopride

Diagnostic studies for Bromopride

Treatment of Bromopride

Continuing Medical Education (CME)

CME Programs on Bromopride


Bromopride en Espanol

Bromopride en Francais


Bromopride in the Marketplace

Patents on Bromopride

Experimental / Informatics

List of terms related to Bromopride

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Bromopride (INN) is a dopamine antagonist with prokinetic properties widely used as an antiemetic, closely related to metoclopramide. It is not available in the United States.

Bromopride appears to be safe and effective for use in pregnancy.[1]


Bromopride is indicated in the treatment of nausea and vomiting, including postoperative nausea and vomiting (PONV); gastroesophageal reflux disease (GERD/GORD); and as preparation for endoscopy and radiographic studies of the gastrointestinal tract. The manufacturer also claims it is valuable in, among other indications, hiccups and gastrointestinal adverse effects of radiation therapy.

Adverse effects

Bromopride is generally well tolerated; the most common adverse effects of its use are somnolence and fatigue. Bromopride may rarely cause extrapyramidal symptoms and, as with metoclopramide, may increase prolactin levels.[2]


Bromopride is a substituted benzamide, closely related to metoclopramide.[3] It is identical to metoclopramide except for the presence of a bromine atom where metoclopramide has a chlorine substituent.


Bromopride is not available in the United States or the United Kingdom. It is marketed in Brazil by Sanofi-Synthélabo under the trade name 'Digesan, by LIBBS under the name Plamet, and as a generic drug.


  1. Araújo JR (1981). "Evaluation of bromopride in nausea and vomiting of pregnancy". J Bras Ginecol (in Portuguese). 91 (4): 283–5. 
  2. "Bula do Profissional de Saúde: Bromoprida". Bulário Eletrônico da Anvisa (in Portuguese). Brazilian National Health Surveillance Agency. April 11, 2006. Retrieved 2007-07-23. 
  3. Brodie RR, Chasseaud LF, Darragh A, Lambe RF, Rooney L, Taylor T (1986). "Pharmacokinetics and bioavailability of the anti-emetic agent bromopride". Biopharm Drug Dispos. 7 (3): 215–22. PMID 3730521. doi:10.1002/bdd.2510070302.